Treats Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive. ANDA 204094, held by Apotex. Aripiprazole.
As of Nov 16, 2026, ANDA 204094 (Aripiprazole), held by Apotex, was first approved by FDA on Sep 30, 2015, with 9 approved supplements and 0 published complete response letters.
Aripiprazole Oral Solution is indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette's disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 30, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Aripiprazole1MG/ML · solution;oral | Aripiprazole | Rx |
| Jan 24, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jan 22, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jan 22, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Feb 5, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 17, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 17, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 23, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 1, 2017 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 18, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 30, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters